(R)-ND-336_product_DataBase

Bioactivity	(R)-ND-336 is a potent and selective MMP-9 inhibitor with a Ki of 19 nM. (R)-ND-336 inhibits MMP-2 (Ki=127 nM) and MMP-14 (Ki=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research[1].
Invitro	(R)-ND-336 poorly inhibits other MMPs (Ki>100 μM). (R)-ND-336 has a long residence time (the time the inhibitor is bound to MMP-9, calculated as 1/koff) of 300 min[1]. A favorable IC50value of 143 μM afforded a therapeutic index (IC50/Ki for MMP-9) ratio of 7530, indicating that (R)-ND-336 is not cytotoxic[1].
In Vivo	(R)-ND-336 (50 μg/wound/day for 14 days) accelerates wound healing faster[1]. (R)-ND-336 has an AUC of 1.3 μM•min after topical administration and 35 μM•min following intravenous dosing, for an AUCtop/AUCiv ratio of 3.7%, indicating minimal absorption after topical administration in db/db mice[1]. Animal Model:
Name	(R)-ND-336
CAS	2252493-33-5
Formula	C16H18ClNO3S2
Molar Mass	371.90
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Trung T Nguyen, et al. Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J Med Chem. 2018 Oct

PeptideDB